8-K: Kewaunee Scientific Reports Mixed Q2 Results Amidst Acquisition Costs and International Delays

Kewaunee Scientific Corporation announced its second quarter fiscal year 2025 results, showing a decrease in overall sales and pre-tax earnings, but an increase in net earnings and a record backlog, while also incurring costs related to the acquisition of Nu Aire, Inc.

Summary

• Kewaunee Scientific Corporation reported a 5.3% decrease in sales for the second quarter of fiscal year 2025, totaling $47.764 million, compared to $50.436 million in the same quarter of the previous year.
• Pre-tax earnings decreased by 18.9% to $3.931 million, down from $4.845 million in the prior year's second quarter.
• Net earnings, however, increased to $3.008 million, compared to $2.732 million in the prior year quarter.
• EBITDA for the quarter was $4.883 million, a decrease from $5.662 million in the prior year quarter.
• Diluted earnings per share increased to $1.01, up from $0.93 in the prior year quarter.
• The company's order backlog reached a record high of $184.4 million on October 31, 2024, compared to $146.3 million on October 31, 2023.
• Domestic sales increased by 6.5% to $36.409 million, while international sales decreased by 30.1% to $11.355 million.
• The company incurred $2.3 million in professional service and other fees related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024.
• Total cash on hand was $29.664 million on October 31, 2024, compared to $25.938 million on April 30, 2024.
• The company's debt-to-equity ratio decreased to 0.59-to-1 on October 31, 2024, from 0.70-to-1 on April 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While the backlog is strong and domestic sales are up, the overall sales and pre-tax earnings are down, and international sales are significantly impacted by delays. The acquisition is a positive, but the costs associated with it are a concern.

Positives

• The company's order backlog is at a record high, indicating strong future demand.
• Domestic segment sales and earnings showed significant improvement due to higher product demand.
• Net earnings and diluted earnings per share increased compared to the prior year quarter.
• The acquisition of Nu Aire, Inc. is expected to expand the company's product offerings and market presence.
• The company's debt-to-equity ratio has improved.

Negatives

• Overall sales decreased by 5.3% compared to the same quarter last year.
• Pre-tax earnings decreased by 18.9% compared to the prior year quarter.
• International sales decreased significantly by 30.1% due to customer construction site delays in India.
• The company incurred $2.3 million in professional service and other fees related to the Nu Aire acquisition.
• Corporate segment pre-tax net loss increased compared to the prior year quarter.

Risks

• Customer construction site delays in India are negatively impacting international sales and earnings.
• The company is facing increased professional service and other fees related to the Nu Aire acquisition.
• The company's performance is subject to fluctuations in operating results from quarter to quarter.
• The company is exposed to risks related to international operations, including foreign currency fluctuations.
• The company is subject to competitive and general economic conditions, including supply disruptions.

Future Outlook

The company's backlog remains very healthy, positioning it well to deliver another strong year. The acquisition of Nu Aire is expected to expand the company's capabilities and market reach, with Nu Aire's results to be included starting in the third quarter of fiscal year 2025.

Management Comments

• Our financial performance for the second quarter of fiscal year 2025 was strong.
• Domestic segment operating performance improved compared to last year's second quarter as a result of higher product demand, highlighting our continued health and advantage in the market.
• Customer construction site delays in India on multiple projects continue to impact our ability to ship products and deliver services, leading to a decrease in sales and earnings when compared to the prior year second quarter.
• Our backlog remains very healthy, demonstrating the continued vitality and investment in the markets in which Kewaunee participates and the success both Kewaunee and our channel partners continue to achieve in the marketplace.
• The strength of Kewaunee's backlog positions the company well to deliver another strong year for our fiscal year.
• The acquisition of Nu Aire presents a unique opportunity for Kewaunee to expand its capabilities, allowing the combined organization to better meet the diverse needs of end-users in laboratory furnishings and, through Nu Aire's established distribution partners, reach regions where Kewaunee has not previously had a presence.
• This move accelerates the Company's vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products essential for outfitting the laboratories of tomorrow.

Industry Context

The laboratory furniture and equipment industry is experiencing continued investment, as evidenced by Kewaunee's record backlog. The acquisition of Nu Aire reflects a trend of consolidation and expansion within the industry, as companies seek to broaden their product offerings and market reach. The delays in India highlight the challenges of international operations and supply chain management in the current global environment.

Comparison to Industry Standards

• Kewaunee's domestic sales growth of 6.5% is a positive sign, indicating strong demand in its primary market, this is comparable to other US based laboratory furniture manufacturers such as Hamilton Scientific who have also reported strong domestic growth.
• The 30.1% decline in international sales due to delays in India is a significant concern, this is worse than some competitors who have diversified their international supply chains and customer base, such as Esco Global.
• The record backlog of $184.4 million suggests strong future revenue potential, this is a positive indicator compared to companies with lower backlogs such as Labconco.
• The acquisition of Nu Aire is a strategic move to expand product offerings and market reach, similar to moves by other companies in the industry to diversify their product portfolios, such as Thermo Fisher Scientific.
• The company's debt-to-equity ratio of 0.59-to-1 is a reasonable level, indicating a healthy balance sheet, this is comparable to other companies in the sector with similar capital structures.

Stakeholder Impact

• Shareholders may be concerned about the decrease in overall sales and pre-tax earnings, but encouraged by the record backlog and the acquisition of Nu Aire.
• Employees may be impacted by the integration of Nu Aire and any potential changes in operations.
• Customers may experience delays in international deliveries due to construction site issues in India.
• Suppliers may see increased demand due to the company's record backlog and the acquisition of Nu Aire.
• Creditors may be reassured by the company's improved debt-to-equity ratio.

Next Steps

• The company will integrate Nu Aire into its operations, with Nu Aire's results to be included starting in the third quarter of fiscal year 2025.
• The company will continue to monitor and address the customer construction site delays in India.
• The company will focus on leveraging its record backlog to drive future revenue growth.

Key Dates

Keywords

Kewaunee Scientific, laboratory furniture, Nu Aire, acquisition, financial results, earnings, backlog, sales, EBITDA, debt-to-equity, international sales, domestic sales